Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.29 USD | -3.32% |
|
+1.96% | +395.92% |
05-30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
05-30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+395.92% | 217M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Transcript : Candel Therapeutics, Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-19-2023 11